Kala Pharmaceuticals has been granted a patent for a method of treating ocular conditions using a fibronectin composition derived from mesenchymal stem cells. The composition excludes certain components to ensure efficacy. GlobalData’s report on Kala Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Kala Pharmaceuticals Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Kala Pharmaceuticals, Cancer treatment biomarkers was a key innovation area identified from patents. Kala Pharmaceuticals's grant share as of February 2024 was 43%. Grant share is based on the ratio of number of grants to total number of patents.

Ocular treatment method using msc-derived fibronectin composition

Source: United States Patent and Trademark Office (USPTO). Credit: Kala Pharmaceuticals Inc

A recently granted patent (Publication Number: US11919942B2) discloses a method for treating ocular conditions using a composition containing fibronectin (FN), specifically mesenchymal stem cell (MSC)-derived FN. The method involves administering the composition, which excludes various components such as xenobiotic components, peptides, and biomolecules <3 kDa, to a subject in need of treatment. The FN can be MSC-secreted or cellular FN, with the cellular FN potentially being Extra Domain A+ (EDA+) and/or Extra Domain B+. The composition may also include growth factors like fibroblast growth factors (FGFs) and platelet-derived growth factor (PDGF) to aid in the treatment of conditions such as ocular wounds, neovascularization, and dry eye disease.

Furthermore, the patent outlines specific concentrations and formulations of the composition, including the addition of tonicity modifying agents like NaCl and mannitol. The method allows for the administration of the composition through topical application or subconjunctival injection, targeting a range of ocular conditions such as damaged corneal surfaces, retina conditions, and persistent corneal epithelial defects. Importantly, the composition excludes components like insulin and hydrocortisone, focusing on the therapeutic potential of MSC-derived FN in treating ocular ailments while avoiding potentially harmful additives like animal serum and non-exosome debris. This patent highlights a novel approach to ocular treatment utilizing the regenerative properties of MSC-derived FN in a carefully curated composition tailored for effective and safe therapeutic outcomes.

To know more about GlobalData’s detailed insights on Kala Pharmaceuticals, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies